Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16103775 | 0.87 | L3MBTL1 (0.43) | L3MBTL1NANP | |
| SCHEMBL16438247 | 0.84 | L3MBTL1 (0.45) | L3MBTL1NANP | |
| SCHEMBL29338118 | 0.84 | L3MBTL1 (0.48) | L3MBTL1NANP | |
| SCHEMBL17471042 | 0.81 | L3MBTL1 (0.45) | L3MBTL1NANP | |
| SCHEMBL14944587 | 0.80 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL17117576 | 0.79 | NANP (0.52) | L3MBTL1NANP | |
| SCHEMBL16135482 | 0.79 | NANP (0.52) | L3MBTL1NANP | |
| SCHEMBL15746561 | 0.79 | NANP (0.52) | L3MBTL1NANP | |
| SCHEMBL27391399 | 0.79 | NANP (0.52) | L3MBTL1NANP | |
| SCHEMBL15133464 | 0.78 | L3MBTL1 (0.46) | L3MBTL1NANP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297846-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9221858-B2 | Sialic acid analogs | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150038693-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-8840926-B2 | Sialic acid analogs | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130122094-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297846-A1 | SIALIC ACID ANALOGS | NEU1, NEU2, NEU3 | L3MBTL1 1717/4885NANP 37/4885 |
| US-20130122094-A1 | SIALIC ACID ANALOGS | NEU1, NEU2, NEU3 | L3MBTL1 1717/4885NANP 37/4885 |
| US-20150038693-A1 | SIALIC ACID ANALOGS | NEU1, NEU2, NEU3 | L3MBTL1 1717/4885NANP 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.